A Randomized, Open-label, Dose-ranging Study in Adults and Pediatric Individuals ≥ 12 years of Age to Assess the Safety, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of AZD7442, for Pre-exposure Prophylaxis of COVID-19

Trial Identifier: D8850C00010
Sponsor: AstraZeneca
NCTID:: NCT05375760
Start Date: June 2022
Primary Completion Date: October 2023
Study Completion Date: October 2023

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Version
Spanish (US) Translation

Trial Locations

Country Location
US, AL Birmingham, AL, US, 35215
US, CA Modesto, CA, US, 95350
US, CA Westminster, CA, US, 92683
US, FL Hollywood, FL, US, 33024
US, FL Lake City, FL, US, 32055
US, FL Miami, FL, US, 33125
US, FL Miami Lakes, FL, US, 33014
US, FL Ormond Beach, FL, US, 32174
US, FL Wesley Chapel, FL, US, 33545
US, FL West Palm Beach, FL, US, 33409
US, IL Chicago, IL, US, 60640
US, MO St Louis, MO, US, 63141
US, TN Knoxville, TN, US, 37920
US, TX El Paso, TX, US, 79925
US, VA Annandale, VA, US, 22003